Literature DB >> 5456013

Amphotericin B serum concentrations during therapy.

B T Fields, J H Bates, R S Abernathy.   

Abstract

Therapeutic outcome of patients being treated for systemic mycoses with amphotericin B is possibly related to the serum concentrations of this drug that are produced in these patients. Because current data are conflicting, the magnitude of these concentrations was restudied by using a bioassay which gave precise and accurate results. The highest of 155 serum concentrations was 2.01 mug/ml. Mean concentrations were 1.21, 0.62, and 0.32 mug/ml, at 1, 18, and 42 hr, respectively, after intravenous infusion of amphotericin B. This drug was detected in serum 7 weeks after completion of treatment, but it could not be detected 13 weeks after treatment. Drug levels did not appreciably decrease in serum stored for 8 to 9 months at - 10 C. Unequal serum content in assay tubes and measurement of assay turbidity by visual inspection may explain previously reported amphotericin B levels of 3.0 to 12.5 mug/ml.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5456013      PMCID: PMC376832          DOI: 10.1128/am.19.6.955-959.1970

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  21 in total

1.  An automatic method for colorimetric analysis.

Authors:  L T SKEGGS
Journal:  Am J Clin Pathol       Date:  1957-09       Impact factor: 2.493

2.  Coccidioidomycosis and its treatment with amphotericin B.

Authors:  M L LITTMAN; P L HOROWITZ; J G SWADEY
Journal:  Am J Med       Date:  1958-04       Impact factor: 4.965

3.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

Authors:  D B LOURIA
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1958-05

4.  The antibiotic therapy of bacterial endocarditis: therapeutic data on 172 patients seen from 1951 through 1957: additional observations on short-term therapy (two weeks) for penicillin-sensitivie streptococcal endocarditis.

Authors:  J E GERACI
Journal:  Med Clin North Am       Date:  1958-07       Impact factor: 5.456

Review 5.  Methods and significance of in vitro testing of bacterial sensitivity to drugs.

Authors:  R G Petersdorf; J C Sherris
Journal:  Am J Med       Date:  1965-11       Impact factor: 4.965

6.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

7.  Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy.

Authors:  D J Drutz; A Spickard; D E Rogers; M G Koenig
Journal:  Am J Med       Date:  1968-09       Impact factor: 4.965

8.  Alternate-day amphotericin B therapy in the treatment of rhinocerebral phycomycosis (mucormycosis).

Authors:  D J Battock; H Grausz; M Bobrowsky; M L Littman
Journal:  Ann Intern Med       Date:  1968-01       Impact factor: 25.391

9.  Effect of lipoproteins on hemolytic and antifungal activity of amphotericin B and other polyene antibiotics.

Authors:  G Rebell
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

10.  Bioassay for hamycin and amphotericin B in serum and other biological fluids.

Authors:  S Shadomy; J A McCay; S I Schwartz
Journal:  Appl Microbiol       Date:  1969-04
View more
  32 in total

1.  Stability of amphotericin B in fungal culture media.

Authors:  S C Cheung; G Medoff; D Schlessinger; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

2.  Effect of amphotericin B and clotrimazole on lymphocyte stimulation.

Authors:  A Tärnvik; S Ansehn
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

3.  Uniform susceptibility of various strains of Coccidioides immitis to amphotericin B.

Authors:  M S Collins; D Pappagianis
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

4.  Combination antifungal therapy for cryptococcal meningitis.

Authors:  J S Tobias; P F Wrigley; E Shaw
Journal:  Postgrad Med J       Date:  1976-05       Impact factor: 2.401

5.  Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

Authors:  V Heinemann; D Bosse; U Jehn; B Kähny; K Wachholz; A Debus; P Scholz; H J Kolb; W Wilmanns
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 6.  Chemistry and biology of the polyene macrolide antibiotics.

Authors:  J M Hamilton-Miller
Journal:  Bacteriol Rev       Date:  1973-06

7.  Speciation and amphotericin B sensitivity studies on blood isolates of Candida from burned patients.

Authors:  D D Stieritz; E J Law; I A Holder
Journal:  J Clin Pathol       Date:  1973-06       Impact factor: 3.411

8.  In vitro susceptibility of isolates of Aspergillus fumigatus and Sporothrix schenckii to amphotericin B.

Authors:  J W Brandsberg; M E French
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

9.  Effect of rapid intravenous infusion on serum concentrations of amphotericin B.

Authors:  B T Fields; J H Bates; R S Abernathy
Journal:  Appl Microbiol       Date:  1971-10

10.  Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum.

Authors:  E Martin; U Schlasius; S Bhakdi
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.